Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-cyclopentyl-6-[2-(3-imidazol-1-yl-propoxy)-phenylamino]-9H-purine-2-carbonitrile
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of 6‑aminopurines, characterized by a purine core substituted with a cyclopentyl group and an imidazole-containing side chain. It is referenced as NVP‑ABI491 and CHEMBL188865 in chemical databases. The molecule has been studied as an experimental agent with potential biological activity, but there is no evidence of clinical development or approved therapeutic use. Its mechanism of action and specific biological targets are not described in public sources[1][5][6].
- Other names
- 9-cyclopentyl-6-[2-(3-imidazol-1-yl-propoxy)-phenylamino]-9H-purine-2-carbonitrile9-cyclopentyl-6-{2-[3-(1H-imidazol-1-yl)propoxy]phenyl}amino}-9H-purine-2-carbonitrile9-cyclopentyl-6-{2-[3-(imidazol–1–yl)propoxy]phenyl}amino)purine–2–carbonitrileIHI
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)DDR1 (Discoidin domain receptor 1)DDR2 (Discoidin domain receptor tyrosine kinase 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on 9-cyclopentyl-6-[2-(3-imidazol-1-yl-propoxy)-phenylamino]-9H-purine-2-carbonitrile.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-cyclopentyl-6-[2-(3-imidazol-1-yl-propoxy)-phenylamino]-9H-purine-2-carbonitrile.